Gosselies, Belgium, July 18, 2022 – Apaxen S.A., a privately-held biotechnology company, developing
novel next generation NLRP3 inflammasome inhibitor drugs for treatment of chronic inflammatory
and auto-immune diseases, announced today that it has appointed Graham K. Dixon, PhD as
Chairman of its Board of Directors and that it is preparing for clinical testing of its lead product MFC-
1040.
The appointment of Dr Graham Dixon as Chairman is an important step in the transformation of
Apaxen from a pre-clinical to a clinical stage company. During his successful carreer in C-suite
management positions at companies such as Galapagos, Addex Therapeutics and Mithra
Pharmaceutical, he was instrumental to the regulatory approval of three pharmaceutical products,
twelve proof of concept studies and ten clinical stage licensing deals. He is an experienced non-
executive director and board chairman as well as an advisor to several venture capital organisations
and their portfolio companies.
In addition, Apaxen expects to complete IND enabling pre-clinical testing of its lead NLRP3
inflammasome inhibitor MFC-1040 by end of 2022 and aims to raise series B round financing by early
2023 to fund the clinical development plans of the company.